TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of platelet engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of acute graft versus host disease (GvHD) by grades
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance of treated warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of daily steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Plasma Concentration-time Profile from Time Zero to Extrapolated Infinite Time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Plasma Concentration-time Profile from Time Zero to the Time of the Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mystical Experience Questionnaire (MEQ-30) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impaired blink quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of Fycompa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with absolute prostate-specific antigen (PSA) response at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with adverse events of special interests (AESIs), serious adverse events (SAEs) and adverse events (AEs) leading to dose modification or discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of procedure-emergent adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of Survival
Endpoint domain: Mortality/survival
Primary endpoint: Evaluate the Quality of Life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hippocampal SV2A synaptic density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cortical activity - change in gamma band power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical activity - change in alpha band power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Dreaming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Dreaming
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Chest Wall Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in exhaled breath VOC profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Investigator-confirmed HAE attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily rating of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of post stroke pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Hospitalizations for Cardiopulmonary, Cardiovascular, Respiratory, Pneumonia/Influenza, Pneumonia and Complications, or RSV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of Hospitalizations for Cardiopulmonary, Cardiovascular, Respiratory, Pneumonia/Influenza, Pneumonia and Complications, or RSV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Hospitalizations for Cardiopulmonary, Cardiovascular, Respiratory, Pneumonia/Influenza, Pneumonia and Complications, or RSV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in ocular redness at 1 hour post-instillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth rate of total GA lesion area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Driving Errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of Physiological indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of BICLA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of sacroiliitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Comprehensive response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Socioeconomic Status (SES)- Individual Subjective SES
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Socioeconomic Status (SES)- Individual Objective SES
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Psychosocial Functioning- World Health Organization (WHO)-Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: absolute change in Numerical Rating Scale (NRS) of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Transfusion Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Antitumor Activity as assessed by RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recurrence of stones in the common bile duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recovery times with Aldrete recovery score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of 1-Hydroxymidazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to usual activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Radiographic evidence of tumor physiological imaging changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in 24-hour ambulatory systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in objectively estimated sleep duration and sleep efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in serum 25(OH)D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to lung cancer screening follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Experiencing Grade 3 or Higher Cytokine Release Syndrome (CRS) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Grade 3 or Higher Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Grade 3 or Higher Neurotoxicity (Ntox) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of complete resections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: The number of resected lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: The duration of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: The length of hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: atrial fibrillation events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in KCCQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in six-minute walk test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RSVPreF3 Specific Immunoglobin (Ig)G Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to admission to a long-term care home
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Whole Cervical Range of Motion (ROM) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Objective Response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children diagnosed with Autism Spectrum Disorder or Neurodevelopmental Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetic microvascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excision completeness at the lateral margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total Radioactivity Recovery and Excretion (TRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for LY4100511
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for LY4100511
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants experiencing local solicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing MAAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing systemic solicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing moderate-severe diarrhea (MSD) with ETEC
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of completing all clinical trial activities
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean root coverage (mRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratinized tissue (KT) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Pain Scores from Baseline to Investigational Product Discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Responders to Average Pain from Baseline to Investigational Product Discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 related emergency department visits
Endpoint domain: Adverse events/effects
Primary endpoint: all cause hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Complete response rate (CRR) at 3-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery times of pregnant women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Respectful birth care scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Birth experience scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Traumatic birth perception scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of any unsolicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of related Grade 3 laboratory toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of related serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Swelling (volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implementation feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in parent report of child's health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in patient-reported health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Correctness of clinical diagnosis of dystonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of clinical diagnosis of dystonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point-prevalence abstinence (PPA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Any 24-hour intentional quit attempt
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of participants eligible for clinical trials
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Advance care conversations attempted, held, documented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fidelity of ACP conversations per the HIGHway process
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relevance and Significance of ACP intervention for patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IL-6 Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: new onset renal failure requiring dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: new focal neurological deficit (stroke)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Linkage to PrEP care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Linkage to employment-related services in community
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Employment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Functional independence Measure (FIM) improvement trajectory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interval Time From Labor Induction to Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Seizure frequency during EMU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Duration of EMU admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Visual analogue score (VAS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3D right ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent change in the body composition index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in seated pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent change in supine pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent change in 6-minute walking test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sympathetic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in detecting csPCa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WBI changes post AVF implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weaning rate from mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline HbA1c at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of bone density around dental implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progression-free Survival rate at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Compression time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of TNP-2092 in synovial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of TNP-2092 in bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum procalcitonin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injectate spread on MRI image
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ganglion Cell Complex Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Central Retinal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain score after fascia iliaca block placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score during positioning of patient for sub-arachnoid block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of Events Scale (IES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in gingival augmentation with microneedling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Adverse Events (AE's) according to frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Adverse Drug Reactions (ADR's) according to frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Serious Adverse Events (SAE's) according to frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Distance visual acuity test via ETDRS chart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance visual acuity self assessment via DDiVAT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of SKTLs achieving PLA score of 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Application Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity after COVID-19 vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: evolution of deep slow-wave sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Modified Oswestery Disability Index (MODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Seroconversion of SARS-CoV-2 neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT of SARS-CoV-2 neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMI of SARS-CoV-2 neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants with Solicited Injection Site Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Unsolicited Injection Site Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Lower limb atheroma plaque inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Generalized Anxiety Disorder Scale-7
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Drug Abuse Screening Test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Michigan Alcohol Screening Test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Birth Satisfaction Scale Short Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity: Number of True Positive AS Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity: Number of True Positive PWS Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity: Number of Healthy Controls With True Negative Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency department rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Life's Essential 8 risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures of Processes of Care (MPOC)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Pediatric Evaluation of Disability Inventory
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Form- 36 scores (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area of dysaesthesia on a patient's chest wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in adjusted heart rate reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Peak VO2 (ml/kg/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postpartum sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Alphabetic communication
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning